- Investing Ideas
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
Results
22
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
22 companies
Celcuity
Market Cap: US$4.0b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$82.46
7D
-10.1%
1Y
114.2%
Tango Therapeutics
Market Cap: US$3.9b
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$26.65
7D
-8.2%
1Y
312.9%
Arcus Biosciences
Market Cap: US$3.5b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$27.05
7D
-8.2%
1Y
181.5%
uniQure
Market Cap: US$2.5b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$36.66
7D
-9.2%
1Y
153.5%
Vera Therapeutics
Market Cap: US$2.5b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$33.32
7D
-10.4%
1Y
60.8%
Iovance Biotherapeutics
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$4.70
7D
-14.2%
1Y
61.0%
Syndax Pharmaceuticals
Market Cap: US$1.7b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$19.63
7D
-11.0%
1Y
96.5%
COMPASS Pathways
Market Cap: US$1.5b
Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.
CMPS
US$10.85
7D
-10.9%
1Y
152.9%
Neurogene
Market Cap: US$689.9m
A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
NGNE
US$33.22
7D
-9.4%
1Y
58.2%
Immix Biopharma
Market Cap: US$618.6m
A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
IMMX
US$8.44
7D
-11.8%
1Y
212.6%
4D Molecular Therapeutics
Market Cap: US$514.1m
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
FDMT
US$9.85
7D
-10.1%
1Y
123.4%
Century Therapeutics
Market Cap: US$376.9m
A biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
IPSC
US$2.05
7D
-8.5%
1Y
251.0%
MacroGenics
Market Cap: US$254.3m
A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
MGNX
US$3.85
7D
-15.2%
1Y
143.7%
Compugen
Market Cap: US$225.1m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.26
7D
-9.2%
1Y
52.7%
Immunic
Market Cap: US$188.1m
A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
IMUX
US$13.34
7D
-11.9%
1Y
36.2%
Karyopharm Therapeutics
Market Cap: US$160.7m
A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
KPTI
US$7.09
7D
-9.9%
1Y
71.7%
Nautilus Biotechnology
Market Cap: US$151.9m
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
NAUT
US$1.20
7D
-29.4%
1Y
57.9%
Kazia Therapeutics
Market Cap: US$139.5m
Operates as an oncology-focused biotechnology company in Israel.
KZIA
US$12.69
7D
-10.3%
1Y
47.2%
PepGen
Market Cap: US$131.4m
A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
PEPG
US$1.83
7D
-13.7%
1Y
32.6%
Cumberland Pharmaceuticals
Market Cap: US$105.3m
A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
CPIX
US$6.81
7D
-13.2%
1Y
95.1%
Clene
Market Cap: US$69.8m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$4.99
7D
-14.7%
1Y
48.5%
Numinus Wellness
Market Cap: US$14.0m
Provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States.
NUMI.F
US$0.04
7D
-19.8%
1Y
60.4%